Key Highlights: Implications: Wegovy’s new MASH indication turns semaglutide into a dual liver–weight disease asset in India, opening a large, under-treated fatty liver market (about two i...
Key Highlights: Implications: Emcure is effectively repositioning Poviztra as a mass‑market GLP‑1 for obesity in India, using a steep 55% entry‑dose cut (now ₹3,999/mon...
